Clinical Trial Update: Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 trial updating the safety and preliminary activity of the oral decitabine/cedazuridine combo (ASTX727) with durvalumab in recurrent and/or metastatic he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Durvalumab (durvalumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-09-16